← Browse by Condition
Medical Condition
focal segmental glomerulosclerosis
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
ClinicalMetric tracks all active clinical trials for focal segmental glomerulosclerosis sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — focal segmental glomerulosclerosis Clinical Trials
How many clinical trials are currently recruiting for focal segmental glomerulosclerosis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for focal segmental glomerulosclerosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for focal segmental glomerulosclerosis?
focal segmental glomerulosclerosis research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a focal segmental glomerulosclerosis clinical trial?
Eligibility criteria for focal segmental glomerulosclerosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 1
Top Sponsors
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06065852
Recruiting
National Registry of Rare Kidney Diseases
Enrollment
35,000 pts
Location
United Kingdom
Sponsor
UK Kidney Association
NCT06500702 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Enrollment
84 pts
Location
United States, Argen...
Sponsor
Sanofi
NCT02235857
Recruiting
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Enrollment
35 pts
Location
United States
Sponsor
Kaneka Medical America LLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology